New York: Omeros Corp (NASDAQ:OMER) Stock Has Just Had Its Hold Rating Reiterated by Wedbush. Shares now Have a $20.0000 Target

May 17, 2018 - By Paula Hilliard

Omeros Corporation (NASDAQ:OMER) Logo

Investors sentiment decreased to 1.3 in 2017 Q4. Its down 1.56, from 2.86 in 2017Q3. It is negative, as 14 investors sold Omeros Corporation shares while 29 reduced holdings. 31 funds opened positions while 25 raised stakes. 21.94 million shares or 0.43% less from 22.04 million shares in 2017Q3 were reported.

State Board Of Administration Of Florida Retirement Sys reported 30,737 shares stake. Trexquant Invest Limited Partnership holds 0.02% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 11,421 shares. Tci Wealth Inc accumulated 100 shares. Parametric Assoc Ltd Liability Com holds 0% in Omeros Corporation (NASDAQ:OMER) or 30,876 shares. Zurcher Kantonalbank (Zurich Cantonalbank), Switzerland-based fund reported 2,779 shares. United Capital Advisers Ltd Co accumulated 101,672 shares or 0.02% of the stock. California-based Lpl Financial Limited Liability has invested 0% in Omeros Corporation (NASDAQ:OMER). Blackrock reported 0% in Omeros Corporation (NASDAQ:OMER). Morgan Stanley reported 157,503 shares or 0% of all its holdings. Washington Tru Bank & Trust owns 5,143 shares. Cypress Cap Gru accumulated 10,000 shares or 0.04% of the stock. Tocqueville Asset Lp owns 290,119 shares or 0.06% of their US portfolio. Department Mb Bancorp N A has invested 0.01% in Omeros Corporation (NASDAQ:OMER). Royal Commercial Bank Of Canada owns 1,200 shares or 0% of their US portfolio. Ameritas Inv Prtnrs has invested 0% of its portfolio in Omeros Corporation (NASDAQ:OMER).

Since January 3, 2018, it had 0 insider purchases, and 2 sales for $1.36 million activity. On Wednesday, January 3 the insider Kelbon Marcia S. sold $1.34 million.

Omeros Corp (NASDAQ:OMER) Rating Reaffirmed

Omeros Corp (NASDAQ:OMER) just had their share rating of a ‘Hold’ issued by research analysts at Wedbush, who now has a $20.0000 PT on the $978.41 million market cap company or a -1.28 % downside potential. This key information was shown in a research report on Wednesday, 16 May.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Among 5 analysts covering Omeros Corp (NASDAQ:OMER), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Omeros Corp has $7500 highest and $25 lowest target. $45.25’s average target is 123.35% above currents $20.26 stock price. Omeros Corp had 15 analyst reports since November 28, 2017 according to SRatingsIntel. Wedbush downgraded the stock to “Neutral” rating in Friday, March 23 report. On Wednesday, November 29 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Hold” rating by Needham given on Friday, March 2. H.C. Wainwright maintained the shares of OMER in report on Tuesday, January 23 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Friday, March 23 report. The rating was maintained by H.C. Wainwright on Friday, May 11 with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $3400 target in Thursday, April 19 report. On Monday, March 5 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm earned “Buy” rating on Thursday, January 4 by H.C. Wainwright. The firm has “Buy” rating given on Wednesday, April 4 by H.C. Wainwright.

The stock increased 1.25% or $0.25 during the last trading session, reaching $20.26. About 1.66M shares traded or 4.48% up from the average. Omeros Corporation (NASDAQ:OMER) has declined 3.39% since May 18, 2017 and is downtrending. It has underperformed by 14.94% the S&P500.

Analysts await Omeros Corporation (NASDAQ:OMER) to report earnings on August, 14. They expect $-0.55 earnings per share, down 139.13 % or $0.32 from last year’s $-0.23 per share. After $-0.53 actual earnings per share reported by Omeros Corporation for the previous quarter, Wall Street now forecasts 3.77 % negative EPS growth.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $978.41 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

More recent Omeros Corporation (NASDAQ:OMER) news were published by: Fool.com which released: “Why Omeros, Party City Holdco, and Overstock.com Slumped Today” on May 16, 2018. Also Seekingalpha.com published the news titled: “Rounds Report: Omeros Rallied Robustly While Stellar FDA Due Diligence To Help Orphan Disease Innovators” on May 16, 2018. Seekingalpha.com‘s news article titled: “Your Daily Pharma Scoop: Omeros Up On Update, Synergy Sales, President’s Healthcare Plans” with publication date: May 14, 2018 was also an interesting one.

Omeros Corporation (NASDAQ:OMER) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: